Antiviral Drugs Market Trends 2021-2027, North America, Europe & APAC Industry Statistics with COVID-19 Impact Analysis: Graphical Research

Share this news:

Europe antiviral drugs market size to cross $8.7 billion valuation by 2027 | Influenza segment to boost growth in North American market | Asia Pacific industry to hit USD 7.2 Bn by 2027

Graphical Research has added a new report on antiviral drugs market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size. Comprising the current and future trends defining the dynamics of this industry vertical, this report also incorporates the regional landscape of market in tandem with its competitive terrain.

The global antiviral drugs industry forecast is anticipated to gain considerably due to the positive influence of the following eight factors:

Growing risk of COVID-19 infection amongst Europeans

The alarming rate of the proliferation of the Coronavirus has led to a marked uptick in the usage of antiviral drugs to treat viral infections throughout European countries as well. Using antiviral drugs can considerably lower the effect of the SARS-CoV-2 virus to a certain extent.

When used with other necessary medications and precautionary measures such as self-isolation, quarantine, and contact tracing, they have been proven to be an effective management solution for COVID-19 patients with mild to moderate symptoms. The trending authorization of prescription drugs has been accelerating Europe antiviral drugs market forecast.

Consumption of generic antiviral drugs in European countries

The generic antiviral drugs segment is advancing at a steady apce in Europe antiviral drugs market. By 2027, the segment is anticipated to claim a prominent market share in terms of revenue, driven by the rising consumption of generic antiviral drugs in the recent times. Using generic drugs can significantly bring down the overall hospital expenses of the patient. As opposed to expensive branded medications, numerous industry players in the region have been introducing cost-effective alternatives to cater to the need for effective medicines amid the pandemic.

Access sample pages of the report, “Europe Antiviral Drugs Market Forecasts 2027” in detail along with the table of contents (ToC) @
https://www.graphicalresearch.com/request/1737/sample

Alarming incidence rate of influenza through North America

The growing number of influenza cases in the U.S., Canada, and other parts of North America have been spurring the expansion of the antiviral drugs consumption. The market share from influenza segment is projected to grow at a 4.5% CAGR up to 2027, aided by the threat of COVID-19 infection. The high incidence of influenza has been leading to a spiraling number of hospitalized patients, pushing the regional antiviral drugs industry forecast.

Spiraling demand for anti-viral therapies in Canada

The Canadian Antiviral Drugs market has been exhibiting significant demand for antiviral prescription drugs, especially in the wake of the coronavirus pandemic. During 2020, the regional market was estimated at $1.5 billion. Increasing density of elderly population, being highly prone to contracting viral infections, has been fostering growth opportunities for drug makers in North America. Anti-viral therapies are gaining traction amongst these patients, with numerous market players launching new antiviral drugs.

Access sample pages of the report, “North America Antiviral Drugs Market Forecasts 2027” in detail along with the table of contents (ToC) @
https://www.graphicalresearch.com/request/1733/sample

Development of new drugs in the United States

The U.S. has been registering a high adoption rate of anti-viral drugs and anti-viral therapies since even before the outbreak of the COVID-19 pandemic. As per the records of the Centers for Disease Control and Prevention (CDC), more than 35.5 million residents were suffering from influenza, resulting in over 490,600 hospitalizations and more than 30,000 deaths across the nation during the 2018-19 season. Additionally, since the U.S. is one of the worst COVID-19 affected countries, the deployment of antiviral drugs is expected to rise further.

Increasing number of product launches in Asia Pacific

The growing number of product launches and full-fledged R&D activities by several Asian pharmaceutical companies can prove to be beneficial for antiviral drug makers in APAC. For instance, during August 2020, Dr Reddy’s Laboratories, an India-based generic drug manufacturer introduced its new antiviral drug, Avigan, intended to be used to treat COVID-19 patients with mild to moderate symptoms. The drug was developed in partnership with Fujifilm Toyama Chemical Co., a Japanese drug company.

Spiraling prevalence of HIV AIDS across Asian countries

The HIV AIDS segment is anticipated to accrue a considerable revenue share of the overall Asia Pacific antiviral drugs market share through 2027. The segment was valued at $3.2 billion during 2020 and is progressing at a substantial CAGR. During 2018, more than 1.25 million individuals were suffering from HIV infection in China, as per the data of the World Health Organization (WHO). Infectious diseases are occurring frequently amongst the Asian citizens. For instance, South Korea is a hotspot of infectious diseases. It might contribute handsomely toward the proliferation of the APAC antiviral drugs industry size.


Pediatric population require antiviral drugs

The pediatric segment in the APAC antiviral drugs market has been presenting considerable expansion prospects in the recent times, thanks to the growing risk of HIV infection amongst children in India and China. The risk of hospital-acquired infections is particularly high amongst newborns. Newborns and children are highly vulnerable to infections due to their undeveloped immune system. The high frequency of HIV infections is expected to drive the antiviral drugs market in Asia Pacific.

Merck & Co. Inc, GlaxoSmithKline plc, Gilead Science, Abbvie, AstraZeneca, Bristol-Myers Squibb, Aurobindo Pharma Ltd., and Johnson & Johnson, are some leading antiviral drug manufacturers across the international landscape.

About Graphical Research:

Graphical Research is a business research firm that provides industry insights, market forecast and strategic inputs through granular research reports and advisory services. We publish targeted research reports with an aim to address varied customer needs, from market penetration and entry strategies to portfolio management and strategic outlook. We understand that business requirements are unique: our syndicate reports are designed to ensure relevance for industry participants across the value chain. We also provide custom reports that are tailored to the exact needs of the customer, with dedicated analyst support across the purchase lifecycle.

Contact Info:
Name: Parikhit B.
Email: Send Email
Organization: Graphical Research
Address: 401, Whispering Wind,
Phone: 18009866917
Website: https://www.graphicalresearch.com

Release ID: 89040310

CONTACT ISSUER
Name: Parikhit B.
Email: Send Email
Organization: Graphical Research
Address: 401, Whispering Wind,
SUBSCRIBE FOR MORE